Mesoblast Limited (NASDAQ:MESO - Get Free Report) traded up 6.2% during trading on Tuesday . The stock traded as high as $12.63 and last traded at $12.59. 81,641 shares were traded during mid-day trading, a decline of 70% from the average session volume of 269,682 shares. The stock had previously closed at $11.85.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.
Get Our Latest Report on Mesoblast
Mesoblast Stock Down 2.7%
The company has a 50-day moving average of $11.18 and a 200 day moving average of $14.01. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.
Institutional Trading of Mesoblast
Institutional investors have recently added to or reduced their stakes in the company. Lindbrook Capital LLC raised its holdings in shares of Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after buying an additional 901 shares during the period. Prosperity Wealth Management Inc. lifted its position in shares of Mesoblast by 2.0% during the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock worth $1,846,000 after purchasing an additional 1,795 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Mesoblast by 41.1% during the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after purchasing an additional 1,891 shares during the period. Barclays PLC bought a new position in Mesoblast in the 4th quarter worth about $38,000. Finally, JPMorgan Chase & Co. bought a new stake in Mesoblast during the 4th quarter valued at $50,000. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
